Rznomics to Present Oral Report on Breakthrough Anti-Cancer Gene Therapy at AACR
Rznomics, a biotechnology company specializing in RNA-based gene therapies, announced on March 5 that it has been selected to deliver an oral...
Search results for "U.S. market"
Busan On Hospital to Introduce Proton Therapy: Expanding to Vietnam and Russia
Busan On Hospital has announced a bold new vision on the occasion of its 16th anniversary, aiming to establish a global medical network and take a...
Alteogen Poised for Surge in Milestone Revenue as Keytruda Qlex and Biosimilars Gain Momentum
Alteogen is set to accelerate its financial growth this year, driven by a surge in milestone payments and royalty...
Onconic’s ‘Nesuparib’ Secures U.S. FDA Orphan Drug Designation for Small Cell Lung Cancer
Onconic Therapeutics announced on the 24th that its novel anti-cancer candidate, 'Nesuparib', has been designated as an...
U.S. and EU Escalate Pressure on China: A Turning Point for K-Bio?
As the United States prepares to announce the initial regulatory targets of the Biosecurity Act this week, market...
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval
South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
Does Mounjaro Harm Eye Health? Long-Term Study Shows Diabetic Retinopathy Risk Actually Drops
Concerns that Eli Lilly’s popular weight-loss and diabetes treatment, Mounjaro, might exacerbate eye complications in...
Samsung Bioepis Set to Launch Eylea Biosimilar in the U.S. Next January
Samsung Bioepis announced on the 12th that it has entered into a patent license agreement with the original developer...
Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?
The prescription drug sales platform 'TrumpRX', named after U. S. President Donald Trump, has officially launched.
High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval
Since the World Health Organization recommended the use of obesity medications for adults last December, the market is...